000			nab a22 7a 4500
999			_c17098 _d17098
003			PC17098
005			20221128123325.0
008			221128b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9621 _aMartínez Montiel, Pilar _eAparato Digestivo
245	0	0	_aInfliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. _h[artículo]
260			_bDigestive diseases and sciences, _c2015
300			_a60(10):3075-84.
500			_aFormato Vancouver: Taxonera C, Barreiro de Acosta M, Calvo M, Saro C, Bastida G, Martín Arranz MD et al. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci. 2015 Oct;60(10):3075-84.
501			_aPMID: 26044830
504			_aContiene 29 referencias
520			_aBackground: The outcomes of infliximab dose escalation in ulcerative colitis (UC) have not been well evaluated. Aims: To assess the short- and long-term outcomes of infliximab dose escalation in a cohort of patients with UC. Methods: This was a multicenter, retrospective, cohort study. All consecutive UC patients who had lost response to infliximab maintenance infusions and who underwent infliximab dose escalation were included. Post-escalation short-term clinical response and remission were evaluated. In the long term, the cumulative probabilities of infliximab failure-free survival and colectomy-free survival were calculated. Predictors of short-term response and event-free survival were estimated using logistic regression analysis and Cox proportional hazard regression analysis. Results: Seventy-nine patients were included. Fifty-four patients (68.4%) achieved short-term clinical response and 41 patients (51.9%) entered in clinical remission. After a median follow-up of 15 months [interquartile range (IQR) 8-26], 33 patients (41.8%) had infliximab failure. Patients with short-term response had a significantly lower adjusted rate of infliximab failure [hazard ratio (HR) 0.24, 95% confidence interval (CI) 0.12-0.49; p < 0.001]. During a median follow-up of 24 months (IQR 13-34), 9 patients (11.4%) needed colectomy. Short-term response was identified as a predictor of colectomy avoidance (HR 0.14; 95% CI 0.03-0.69; p < 0.007). Conclusions: In UC patients who lost response to infliximab during maintenance, infliximab dose escalation enabled recovery of short-term response in nearly 70% of patients. In the long term, 58% of patients maintained sustained clinical benefit, and 9 of 10 avoided colectomy. Short-term response was associated with an 86% reduction in the relative risk of colectomy.
710			_9273 _aServicio de Medicina del Aparato Digestivo
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17098.pdf _ySolicitar documento
942			_2ddc _cART _n0